PROTAC SARS-CoV-2 Mpro degrader-3

PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) (3-5 days) inhibits the replication of HCoV-229E in Huh-7 cells with an EC₅₀ of 4.6 μM, and shows no cytotoxicity at a concentration of 100 μM^[1].
PROTAC SARS-CoV-2 Mpro degrader-3 (3-5 days) inhibits the replication of HCoV-OC43 in RD cells, with an EC₅₀ of 4.6 μM^[1].
PROTAC SARS-CoV-2 Mpro degrader-3 (3-5 days) inhibits the replication of SARS-CoV-2 in Vero cells, with an EC₅₀ of 0.71 μM^[1].
PROTAC SARS-CoV-2 Mpro degrader-3 (pre-incubated for 15 min; substrate incubated for 1 h) inhibits purified SARS-CoV-2 Mpro, with an IC₅₀ of 0.748 μM and a K_d of 37 μM^[1].
PROTAC SARS-CoV-2 Mpro degrader-3 binds to the purified VCB E3 ligase complex with a K_d value of 37 nM^[1].
PROTAC SARS-CoV-2 Mpro degrader-3 (injected at 50 μM for 120 seconds, followed by injection of 0.25/1 μM VCB for 120 seconds) forms a ternary complex with purified SARS-CoV-2 Mpro and the VCB E3 ligase complex^[1].
PROTAC SARS-CoV-2 Mpro degrader-3 (compound P2) (1.5-50 μM; 24 h, with 4 h GC376 pre-incubation) induces SARS-CoV-2 Mpro degradation in stably transfected HEK 293T cells, with a DC₅₀ of 27 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.